Analysis of the Role of T-cell Response in Patients With Atrial Fibrillation for Clinical Application
1 other identifier
observational
100
1 country
1
Brief Summary
The purpose of this study is 1) to characterize T-cell response in patients with atrial fibrillation, and 2) to analyze the changes of T-cell response after radio-frequency catheter ablation of atrial fibrillation. First, immune-phenotyping and cytokine profiling of T cells from patients with atrial fibrillation will performed. Next the difference of T-cell immunity among various type of atrial fibrillation patients will be analyzed. Finally the changes of T-cell response and cytokines after radio-frequency catheter ablation of atrial fibrillation will be assessed.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2015
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2015
CompletedFirst Submitted
Initial submission to the registry
April 8, 2015
CompletedFirst Posted
Study publicly available on registry
April 21, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2020
CompletedJuly 17, 2018
July 1, 2018
4.9 years
April 8, 2015
July 15, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
The frequency (%) of specific marker-expressing cells among CD4 or CD8 T-subsets
* Immunosenescence marker: CD28, CD57 * Activation marker: CD38, HLA-DR * Differentiation marker: CCR7, CD45RA
1 year
Secondary Outcomes (1)
The frequency (%) of cytokine-secreting cells among CD4 or CD8 T-subsets
1 year
Study Arms (1)
group 1
Atrial fibrillation patients
Interventions
radio-frequency catheter ablation of atrial fibrillation
Eligibility Criteria
patients with atrial fibrillation
You may qualify if:
- Patients who consent with study
- patients with age more than19
- patients who undergoing catheter ablation of atrial fibrillation due to symptomatic, drug refractory atrial fibrillation
You may not qualify if:
- Permanent AF refractory to electrical cardioversion
- AF with rheumatic valvular disease
- Patients with left atrial diameter greater than 60mm
- Patients with age less than 19
- Patient with malignant tumor and chronic infection disease
- Patient are given immune inhibitor and steroidal anti-inflammatory drug within 2weeks
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Severance Cardiovascular Hospital, Yonsei University Health System
Seoul, 120-752, South Korea
Biospecimen
40cc blood sampling
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 8, 2015
First Posted
April 21, 2015
Study Start
April 1, 2015
Primary Completion
March 1, 2020
Study Completion
March 1, 2020
Last Updated
July 17, 2018
Record last verified: 2018-07